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Abstract
Background: The metastatic spread of solid tumors is directly or indirectly responsible for most cancer-related
deaths. Tumor metastasis is very complex and this process requires a tumor cell to acquire enhanced motility,
invasiveness and anoikis resistance to successfully establish a tumor at a distal site. Metastatic potential of tumor
cells is directly correlated with the expression levels of several angiogenic cytokines. Copper is a mandatory
cofactor for the function of many of these angiogenic mediators as well as other proteins that play an important
role in tumor cell motility and invasiveness. We have previously shown that tetrathiomolybdate (TM) is a potent
chelator of copper and it mediates its anti-tumor effects by suppressing tumor angiogenesis. However, very little is
known about the effect of TM on tumor cell function and tumor metastasis. In this study, we explored the
mechanisms underlying TM-mediated inhibition of tumor metastasis.
Results: We used two in vivo models to examine the effects of TM on tumor metastasis. Animals treated with TM
showed a significant decrease in lung metastasis in both in vivo models as compared to the control group. In
addition, tumor cells from the lungs of TM treated animals developed significantly smaller colonies and these
colonies had significantly fewer tumor cells. TM treatment significantly decreased tumor cell motility and
invasiveness by inhibiting lysyl oxidase (LOX) activity, FAK activation and MMP2 levels. Furthermore, TM treatment
significantly enhanced tumor cell anoikis by activating p38 MAPK cell death pathway and by downregulating XIAP
survival protein expression.
Conclusions: Taken together, these results suggest that TM is a potent suppressor of head and neck tumor
metastasis by modulating key regulators of tumor cell motility, invasiveness and anoikis resistance.
Background
Head and neck squamous cell carcinoma (HNSCC) is
the sixth most frequent cancer worldwide and five-year
survival rates (< 50%) are among the lowest of the
major cancers [1,2]. The high mortality associated with
advanced head and neck cancers is in large part due to
the local spread by primary tumors as well as distal
tumor metastasis to vital organs [3,4]. Pulmonary metas-
tases are the most frequent in HNSCC, accounting for
66% of distal metastases. Other metastatic sites include
bone (22%), liver (10%), skin, mediastinum and bone
marrow [4]. HNSCC tumors and their vasculature
express numerous angiogenic cytokines including vascu-
lar endothelial growth factor (VEGF), interleukin (IL)
1a, IL-6, IL-8, and fibroblast growth factor (FGF) [5-7]
which facilitate tumor growth and progression. We and
others have demonstrated that VEGF expression directly
correlates with poor prognosis in head and neck cancer
patients [8-11]. We have recently shown that VEGF, in
addition to its pro-angiogenic function, also induces the
expression of Bcl-2 in the microvascular endothelial
cells [12]. Furthermore, tumor samples from head and
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expression in tumor blood vessels [13] and this
enhanced Bcl-2 expression in tumor-associated endothe-
lial cells was directly correlated with metastatic status of
these patients [14]. Upregulated Bcl-2 expression in
tumor-associated endothelial cells was sufficient to
enhance tumor angiogenesis, tumor progression and
tumor metastasis of oral squamous cell carcinoma in a
SCID mouse model [14].
Tumor metastasis is a complex process consisting of
multiple individual steps [15]. The metastatic process
requires a tumor cell to acquire the ability to migrate
through the primary tumor mass, intravasate and sur-
vive in blood or lymphatic vascular system, and extrava-
sate from the vascular system into a secondary organ to
form the metastatic nodules. A key process in basic cell
migration is the ability of a cell to form a stable adhe-
sion to the extracellular matrix [16]. This process is
regulated by two key proteins within cell: Src and focal
adhesion kinase (FAK) [17]. Inactivation of either of
these proteins leads to dramatic loss in the cell motility.
FAK activation in squamous cell carcinoma and lung
adenocarcinoma has been shown to promote cell inva-
sion [18,19]. In addition, FAK signaling alters matrix
metalloproteinases (MMPs, a family of zinc-containing
endopeptidases that degrade various components of the
extracellular matrix) expression and promotes the gen-
eration of an invasive cell phenotype. Overexpression of
MMP-2 in tumor tissue has been linked with tumor
invasion, metastasis and poor survival in many tumor
types including HNSCC [20-22]. FAK gene silencing by
RNA interference also inhibited tumor cell metastasis by
promoting tumor cell anoikis (anchorage-dependent
cells undergoing cell death due to cell detachment) [23].
Recently Payne et al, have demonstrated that lysyl oxi-
dase (LOX), a copper dependent kinase, promotes
tumor cell migration and invasiveness via the activation
of FAK [24].
Anti-cancer therapy involving copper suppression has
been shown to be an effective inhibitor of angiogenesis
[25,26]. Copper is an essential trace element whose dis-
tinct angiogenic properties were first discovered in the
early 1980’s [27]. Copper has since shown to be a direct
stimulator of endothelial cell proliferation and migration
[27,28]. Additionally, copper is a required cofactor for
the activity, production and secretion of key angiogenic
cytokines up-regulated in head and neck cancers [5,29].
Tetrathiomolybdate (TM) is a potent chelator of copper
that has been widely studied for its good oral bioavail-
ability, low toxicity profile and its tumor suppressive
effects [25,30,31]. We have previously shown that TM is
a potent angiogenesis inhibitor and inhibits tumor
growth and tumor metastasis [5,29]. However, the mole-
cular mechanisms by which TM inhibits tumor
metastasis are poorly understood. In this study, we have
examined the role and mechanisms of TM-mediated
inhibition of tumor metastasis. Our results suggest that
TM treatment significantly inhibits HNSCC metastasis
by decreasing tumor cell motility by inhibiting lysyl oxi-
dase and focal adhesion kinase. In addition, TM treat-
ment inhibited tumor cell invasiveness by down-
regulating MMP2 levels. Moreover, TM treatment also
significantly enhanced tumor cell anoikis by activating
p38 MAPK cell death pathway and downregulating
XIAP survival proteins.
Methods
Cell cultures
Primary human dermal microvascular endothelial cells
(ECs) were purchased from Lonza (Walkersville, MD).
ECs were maintained in Endothelial Cell Basal Medium-
2 (EBM-2) containing 5% FBS and growth supplements.
Oral squamous carcinoma cells (OSCC-3, a kind gift
from M. Lingen, University of Chicago) were maintained
in Dulbecco’s Modified Eagle Medium (DMEM) supple-
mented with 10% FBS.
Transduction of endothelial cells with Bcl-2
Bcl-2 was introduced into human microvascular
endothelial cells(ECs) as described previously [32]. The
Bcl-2 construct or the vector alone was introduced into
PA317 amphotropic packing cells with Lipofectin. Viral
supernatants were collected after 24 hours, centrifuged,
filtered, and stored at -70°C. ECs were transduced with
either Bcl-2 (EC-Bcl-2) or control vector (EC-VC) by
overnight incubation with one-tenth dilution of the viral
supernatant in the presence of 6 μg/ml polybrene.
Transduced ECs were selected by treating them with
G418 (200 μg/ml) for one week. Bcl-2 expression in
endothelial cells was confirmed by Western blot
analysis.
Generation of oral squamous cell line stably expressing
luciferase
Tumor cells (OSCC-3) were transfected with pcDNA3.1
plasmid containing the firefly luciferase gene [33] (a gift
from Dr. Alnawaz Rehemtulla, University of Michigan,
Ann Arbor) using Lipofectamine 2000 as described pre-
viously [34]. Four μg of each plasmid and 20 μl of Lipo-
fectamine 2000 reagent were separately diluted in 200 μl
of DMEM and incubated for 45 minutes at room tem-
perature. The two solutions were gently mixed and
further incubated for 15 minutes at room temperature
to prepare the lipid-DNA complexes. Subsequently, 1.6
ml of DMEM containing 5% FBS was gently mixed with
lipid-DNA complexes. Tumor cells were washed twice
with DMEM and then lipid-DNA complexes were over-
laid onto the cells. The cells were incubated for 6 hours
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tion, DNA containing medium was removed and
replaced with DMEM. Luciferase transduced OSCC-3
(OSCC-3-Luc) cells were selected by incubating in
DMEM containing 400 μg/ml G418 for 7 days.
Tumor metastasis models
We used two in vivo models (flank xenograft and tail
vein injection models) to study the effects of TM on
tumor metastasis.
SCID mouse flank xenograft model
Six weeks old female SCID mice were used in this study.
Animals were randomized to receive either TM or steri-
lized water, delivered daily p.o. gavaging. The treatment
was initiated 2 weeks prior to the tumor inoculation and
continued until the end of the experiment. Plasma ceru-
loplasmin is a good surrogate marker for total body cop-
per status therefore ceruloplasmin levels were measured
using oxidase assay as described before [25]. The base-
line levels of plasma ceruloplasmin were determined for
the TM group before initiation of treatment. Subse-
quently, ceruloplasmin levels were measured biweekly
over the study periods. TM treatment was started at 0.7
mg/day per mouse and then titrated biweekly to main-
tain ceruloplasmin suppression at 20% to 30% of base-
line. OSCC-3-Luc (1 × 10
6) and endothelial cells (EC-
VC or EC-Bcl-2, 1 × 10
6) were mixed with 100 μlo f
Matrigel and injected subcutaneously in the flanks of
SCID mice [14]. Tumor volume measurements began
on day 3 and continued twice a week until the end of
the study. The length and width of the tumors were
measured using a digital caliper and tumor volumes
were calculated using the formula, volume (mm
3)=L×
W
2/2 (length L, mm; width W, mm). After 3 weeks, pri-
mary tumors and lungs were carefully removed and ana-
lyzed for tumor growth, tumor angiogenesis and tumor
metastasis to lungs. Lungs from each mouse were
divided into two parts. One half of each lung was fixed
with 10% buffered formalin and then processed to form
paraffin embedded tissue blocks for immunohistochem-
istry. The other half of the lung was used to harvest
tumor cells. Lungs were finely minced by scissors,
washed with sterile serum free media (DMEM) and trea-
ted with collagenase (2.5 mg/ml) for 3 hours at 37°C
with intermittent shaking. After collagenase treatment,
cells were plated in 10 cm culture dishes and treated
with G418 (400 μg/ml) to select tumor cells (OSCC-3-
Luc). After one week, tumor cell colonies were counted
using phase contrast microscope (50×).
Tail vein metastasis model
In this study, SCID mice were treated with TM as
described above. OSCC-3-Luc cells (0.5 × 10
5)i n5 0μl
volume were injected in the SCID mice via tail vein
using 30 gauge needles. Tumor metastasis to lungs was
monitored by in vivo bioluminescence imaging. After 3
weeks, lungs were carefully removed and tumor meta-
stasis to lungs was analyzed as described above.
In vivo Bioluminescence Imaging
Mice were imaged on a cryogenically cooled imaging
system (Xenogen, Alameda, CA, USA) coupled to a data
acquisition computer. Mice were anesthetized (1.5% Iso-
flurane/air mixture), and injected with luciferin in PBS
at a dose of 320 mg/kg body weight. Digital gray images
were captured and overlaid with pseudocolor images,
which represent photon counts emitted from active luci-
ferase within viable tumor cells. Luminescence emitted
from each animal was integrated for one-minute inter-
vals, from 5-20 minutes after the injection of Luciferin.
Image processing and photon count quantitation were
conducted by means of Living Image software
(Xenogen).
Quantitaion of angiogenesis by immunolocalization of
von Willebrand Factor
Tissue sections were deparaffinized and antigen retrieval
was achieved by pressure cooking in a Decloaking
chamber (Biocare Medical, Walnut Creek, CA) at 120°C
for 20 minutes [35]. Tissue sections were then treated
with peroxide block solution for 5 minutes at room
temperature followed by 1 hour of incubation with pri-
mary antibody (anti-von Willebrand Factor, Dako, Car-
pinteria, CA) at room temperature. Slides were further
incubated for 30 minutes with HRP labeled polymer
(Dako EnVision+ Kit, Carpinteria, CA) and developed
with AEC+chromagen. Microvessel density was calcu-
lated by counting 5 random high power fields (200×).
Tumor cell motility assay
Random cell motility was determined using a motility
assay kit (Cellomics, Pittsburgh, PA) as per manufac-
turer’s instructions. In brief, OSCC-3 cells were har-
vested, suspended in serum-free medium and plated on
top of a field of microscopic fluorescent beads in the
presence or absence of TM (1 nM). After a 16-hours
incubation period, cells were fixed and areas of clearing
in the fluorescent bead field corresponding to phagoki-
netic cell tracks were quantified using NIH ScionImager.
Lysyl oxidase (LOX) activity assay
LOX activity of whole-cell lysates was measured using
the Amplex Red fluorescence assay kit (Molecular
Probes, Eugene, OR). The assay reaction mixture con-
sisted of 50 mM sodium borate (pH 8.2), 1.2 M urea,
50 μM Amplex Red, 0.1 units/ml horseradish peroxi-
dase, and 10 mM 1,5-diaminopentane substrate. TM
treated or untreated control protein samples were added
to the reaction mixture and incubated at 37°C. The
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for 2 hours using a Synergy 4 multidetection microplate
reader (BioTek, Winooski, VT). LOX activity is
expressed as fluorescent units.
Western Blot Analysis
OSCC-3 cells were cultured in 6-well plates and treated
with TM for different time points. Whole cell lysates
were separated by 4-12% NuPAGE Bis-Tris gels (Invitro-
gen, Carlsbad, CA) and transferred onto nitrocellulose
membranes using NuPAGE transfer buffer (Invitrogen,
Carlsbad, CA). To block nonspecific binding, membranes
were incubated with 5% non-fat milk in Tris buffered sal-
ine containing 0.1% Tween-20 (TBST) for 1 hour at
room temperature. Afterwards, the blots were incubated
in the respective primary antibody in TBST + 5% non-fat
milk at 4°C overnight. After washing with TBST, the
blots were incubated with horseradish peroxidase-conju-
gated sheep anti-mouse IgG (1:10,000) or with goat anti-
rabbit IgG (1:10,000) for 1 hour at room temperature. An
ECL-plus detection system (Amersham Life Sciences, Pis-
cataway, NJ) was used to detect specific protein bands.
Protein loading in all the experiments was normalized by
stripping the blots and then re-probing with anti-tubulin
antibody.
Tumor cell invasion assays
The role of TM in tumor cell invasion was investigated
using a Matrigel invasion assay [14]. 24-well plate
inserts (8 μM pore size, Falcon) were coated with 20 μl
of Matrigel and incubated at 37°C for 30 minutes to let
the Matrigel polymerize. Next, 50,000 tumor cells
(OSCC-3) were carefully layered on top of the Matrigel
and the inserts were placed in the 24 well plates in the
presence or absence of TM (1 nM). The plates were
further incubated for 24 hours at 37°C and the non-
invaded cells were carefully removed with a cotton
swab. The inserts were then stained with Diff-quick
solution II and mounted on glass slides. The number of
cells that had invaded through the Matrigel was counted
in 5 high power fields.
MMP analysis by zymography
OSCC-3 cells (5 × 10
5) were cultured in a 6-well plate.
Separately, EC-VC or EC-Bcl-2 (5 × 10
5) cells were pla-
ted on top of collagen coated inserts and then these
inserts were carefully placed in the 6-well plates con-
taining OSCC-3 cells in the presence or absence of TM
(1 nM). After 24 hours, OSCC-3 cells were washed and
further cultured in serum free media (DMEM) for 24
hours. At the end of incubation, culture supernatants
were collected and mixed with non-reducing SDS gel
sample buffer (3:1) and applied without boiling to a 10%
polyacrylamide gelatin gel (Invitrogen, Carlsbad, CA).
After electrophoresis, the gels were washed with ddH2O
and incubated in renaturing buffer (50 mM Tris-HCl,
pH 7.5) containing 2% Triton X-100 for 30 minutes at
room temperature, and then incubated in developing
buffer (50 mM Tris-HCl, pH 7.5) containing 5 mM
CaCl2 and 1 M ZnCl2 at 37°C for 16 hours. Gels were
stained by 0.5% Coomassie Brilliant Blue R-250 solution
to visualize the bands. The band density was measured
using Alpha Imager software (Alpha Innotech, San
Leandro, CA).
Tumor cell anoikis assay
To evaluate the tumor cell anoikis in non-adherent con-
ditions, OSCC-3 cells (5 × 10
5)w e r ec u l t u r e di na6 -
well plate over a thick layer of 1% agar in DMEM con-
taining 2% serum. Tumor cells cultured in adherent
conditions were used as a control. In the TM treatment
experiments, tumor cells were pre-treated with TM (1
nM) for 24 hours and then cultured on top of 1% agar.
At the end of incubation, cells were carefully retrieved
and analyzed by TUNEL staining for anoikis [12]. In
brief, tumor cells were fixed with cytofix buffer (BD
cytofix, BD Biosciences, San Jose, CA) for 15 minutes at
4°C, and then stored overnight in 70% ethanol at -20°C.
The percentage of apoptotic cells were then evaluated
using the APO-BRDU terminal deoxynucleotidyl trans-
ferase (TdT)-mediated dUTP-biotin nick end labeling
(TUNEL) assay according to the manufacturer’s instruc-
t i o n s( S i g m a ,S t .L o u i s ,M O ) .A p o p t o t i ct u m o rc e l l s
were quantitated by flow cytometry using an argon laser
excited at 488 nm (BD Biosciences, San Jose, CA).
Statistical analysis
Data from all the experiments are expressed as mean ±
SEM. Statistical differences were determined by two-way
analysis of variance and Student’stt e s t .Apv a l u eo f
< 0.05 was considered significant.
Results
TM treatment significantly inhibited EC-Bcl-2 mediated
tumor growth and angiogenesis
We have previously shown that elevated expression of
Bcl-2 in tumor-associated endothelial cells directly cor-
relates with tumor metastasis in head and neck cancer
patients [14]. In addition, we also demonstrated that co-
implantation of EC-Bcl-2 along with oral squamous car-
cinoma cells (OSCC-3) in SCID mice significantly
enhances tumor growth and tumor metastasis to lungs.
In this study, we examined if treatment with an anti-
angiogenic agent (tetrathiomolybdate, TM) could inhibit
tumor growth and tumor angiogenesis in this aggressive
squamous cell carcinoma model. The level of plasma
ceruloplasmin, which is a good surrogate marker for
total body copper status, was monitored biweekly and
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plasmin suppression at 20% to 30% of baseline. OSCC-3
tumors containing EC-Bcl-2 showed significantly higher
tumor growth (Fig. 1A) as compared to OSCC-3 tumors
containing endothelial cells with vector alone (EC-VC).
In addition, OSCC-3 tumors containing EC-Bcl-2
showed significantly higher tumor weight (Fig. 1B) at
t h ee n do fs t u d ya sc o m p a r e dt oO S C C - 3c o n t a i n i n g
EC-VC. TM treatment significantly inhibited tumor
growth and tumor weights in OSCC-3 tumor containing
EC-Bcl-2. In addition, TM treatment significantly inhib-
ited blood vessel density in OSCC-3 tumors containing
EC-Bcl-2 cells (Fig. 1C-D). TM treatment did not cause
any animal mortality or induce significant decrease in
body weight (less than 5% weight loss in TM treatment
as compared control, data not shown). TM treatment
also did not induce any systemic toxicity such as
respiratory depression or dry scaly skin.
TM treatment significantly inhibited tumor metastasis to
lungs
We used two in vivo models (flank xenograft and tail
vein injection models) to examine if TM treatment
could inhibit tumor metastasis. OSCC-3 tumors popu-
lated with EC-Bcl-2 showed significantly higher metasta-
sis to lungs as compared to OSCC-3 tumors populated
with EC-VC (Fig. 2). In addition to higher number of
metastatic nodules, OSCC-3 tumors containing EC-Bcl-
2 also had larger lung metastasis nodes (Fig. 2B). Lungs
harvested from animals co-implanted with OSCC-3 and
EC-VC EC-Bcl-2
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Figure 1 Tetrathiomolybdate (TM) treatment significantly inhibits HNSCC tumor growth and tumor angiogenesis. OSCC-3 and EC-Bcl-2
or EC-VC cells were mixed with 100 μl of Matrigel and injected in the flanks of SCID mice. Tumor volume measurements began on day 3 and
continued twice a week until the end of the study. Length and width were measured using a digital caliper and tumor volumes were calculated
using the formula, volume (mm
3)=L×W
2/2 (length L, mm; width W, mm). A; tumor progression curves for different experimental groups:
OSCC-3 plus endothelial cells transduced with vector alone (EC-VC); OSCC-3 plus endothelial cells transduced with vector alone and treated with
TM (EC-VC+TM); OSCC-3 plus endothelial cells transduced with Bcl-2 (EC-Bcl-2); OSCC-3 plus endothelial cells transduced with Bcl-2 and treated
with TM (EC-Bcl-2+TM). B; tumor weights at the end of the study. C-D; Paraffin embedded tumor sections were stained for tumor blood vessels
using anti-human von Willebrand Factor antibodies. Microvessel density in the tumor samples was calculated by counting 5 random fields (x
200). *, represents a significant difference (p < 0.05) as compared to the control group.
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and contained significantly higher number of cells as
compared to OSCC-3 and EC-VC group. TM treated
animals showed significantly lower number of tumor
cell colonies and cells (Fig. 2C-D).
In the tail vein metastasis model, TM treatment mark-
edly inhibited tumor metastasis to lungs at both day 16
and 21 (Fig. 3A-B). Similarly, lungs harvested from TM
treated animals showed significantly lower number of
colonies and tumor cells (Fig. 3C-D).
TM treatment markedly reduced oral squamous cell
motility and invasiveness
Tumor cells cultured in the presence of serum (S+)
exhibited significantly higher motility as compared to
tumor cells cultured in the absence of serum (S-). TM
treatment significantly inhibited tumor cell motility both
i nt h ep r e s e n c e( S + T M + )a n da b s e n c e( S - T M + )o f
serum (Fig. 4A-B). Lysyl oxidase (LOX), a copper-
dependent amine oxidase, has been shown to promote
tumor cell migration and invasion [24]. We next exam-
ined if TM mediated its inhibitory effect on tumor cell
motility by inhibiting LOX. Indeed, TM treatment of
OSCC-3 cells significantly inhibited LOX activity (Fig.
4C). In addition, TM also inhibited the activation of
focal adhesion kinase (FAK), an important cell migration
mediator (Fig. 4D).
In the next set of experiments, we examined if TM
affects OSCC-3 cell invasiveness. TM treatment signifi-
cantly inhibited OSCC-3 invasiveness (Fig. 5A-B).
Matrix matelloproteinases (MMPs) plays an important
role in tumor cell invasiveness by degrading extracellular
matrix. We also examined whether EC-Bcl-2 cells could
enhance MMPs production by OSCC-3 cells and if TM
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Figure 2 TM treatment significantly inhibits EC-Bcl-2 mediated HNSCC tumor metastasis. OSCC-3 and EC-Bcl-2 or EC-VC were mixed with
100 μl of Matrigel and injected in the flanks of SCID mice. Lungs from SCID mice were carefully removed on day 21. One half of each lung was
fixed and paraffin embedded for immunohistochemical analysis. From the other half of the lung, tumor cells were harvested and selected by
G418 treatment. A; representative gross lungs photomicrograph from different experimental groups. B; representative photomicrograph of lung
sections from different experimental groups. C; Number of tumor cell colonies present in different groups. D; Number of tumor cell present in
different groups. *, represents a significant difference (p < 0.05) as compared to the control group.
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cells co-cultured with EC-Bcl-2 showed significant
increase in MMP2 secretion as compared to OSCC-3
cells co-cultured with EC-VC (Fig. 5A-B). TM treatment
of EC-Bcl-2 and OSCC-3 significantly inhibited MMP2
production (Fig. 5C-D).
TM treatment significantly inhibited tumor cell anoikis
In our tail vein metastasis model, we observed signifi-
cant inhibition of tumor metastasis in TM treated ani-
mals. We further examined if TM inhibits tumor
metastasis in tail vein model by promoting tumor cell
anoikis. TM treatment significantly enhanced tumor cell
anoikis in a time dependent manner (Fig 6A). Interest-
ingly, TM had no effect on adherent OSCC-3 cells
(Fig 6A). Survival proteins XIAP and Bcl-2 play an
important role in anoikis resistance. We next examined
if TM treatment downregulates the expression of these
survival proteins in non-adherent conditions. TM treat-
ment markedly downregulated XIAP protein expression
in a time dependent manner (Fig. 6B). However, TM
treatment did not alter the Bcl-2 expression (data not
shown). Moreover, TM treatment also activated stress
activated p38 MAPK cell death signaling pathway
(Fig. 6B).
Discussion
Distant metastases in head and neck cancer almost
invariably herald a poor prognosis with an average survi-
val of 6 months and treatment is usually palliative [36].
Five year survival rates for early stage localized head and
neck cancers are over 80% but this drop to 40% where
disease has spread to neck nodes, and to below 20% for
patients with distant metastatic disease [37]. Currently
used treatment regimens (surgery and/or chemo-radia-
tion) are often ineffective in controlling the metastatic
spread of disease [3]. It is therefore very important to
develop novel therapies for patients with metastatic dis-
ease. Copper is a mandatory cofactor for a number of
proteins that play an important role in angiogenesis,
tumor cell migration and survival [38]. We have pre-
viously shown that TM, a potent copper chelator, inhi-
bits tumor growth and tumor metastasis by suppressing
angiogenesis [29]. Recently, Juarez et al, have shown
that TM attenuates angiogenesis and tumor cell prolif-
eration by inhibiting superoxide dismutase 1 (SOD1)
[30]. However, very little is known about the role of TM
on key metastatic processes, particularly tumor cell
migration, invasion and anoikis resistance. In this study,
we have examined the mechanisms by which TM inhi-
bits tumor cell motility, invasiveness and anoikis
resistance.
We used two in vivo models (flank xenograft model
and tail vein model) to test the efficacy of TM in inhi-
biting tumor metastasis. In the first in vivo model, oral
squamous carcinoma cells (OSCC-3) were co-implanted
along with endothelial cells expressing Bcl-2 (EC-Bcl-2)
in the flanks of SCID mice [14]. The rationale for co-
implanting EC-Bcl-2 along with OSCC-3 is based on
our previous work where we have demonstrated that
co-implantation of EC-Bcl-2 along with tumor cells sig-
nificantly enhances tumor metastasis. In addition, these
EC-Bcl-2 containing tumors exhibited highly invasive
phenotype and abnormal vascular network as commonly
observed with aggressive human tumors. Therefore, this
highly aggressive xenograft model is ideally suited to
test the efficacy of TM on tumor metastasis. Our results
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Figure 3 TM treatment significantly inhibits HNSCC tumor
metastasis. OSCC-3-Luc cells were injected in the SCID mice via tail
vein. Tumor metastasis to lungs was monitored by in vivo
bioluminescence imaging. A; representative photomicrograph of
animals treated with (TM+) or without TM (TM-) at days 16 and 21.
B; Quantitative data of bioluminescence imagining as expressed as
flux units. C; Tumor cells from lungs were harvested and tumor cell
colonies were selected by G418 treatment (200 μg/ml) for one
week and counted. D; Tumor cell colonies were then trypsinized
and total number of cells were counted. *, represents a significant
difference (p < 0.05) as compared to the control group.
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multiple steps that are involved in tumor metastasis
cascade (tumor cell migration, invasion and survival in
circulation) to reach the distal site.
Tumor cell motility and invasiveness are key characteris-
tics of aggressive metastatic tumors as they play an impor-
tant role in tumor cell release from the primary tumors
into the circulation. To examine if TM treatment affects
tumor cell motility, we used a random cell motility assay.
TM treatment significantly inhibited tumor cell motility
b o t hi nt h ep r e s e n c ea n di nt h ea b s e n c eo fs e r u m .C e l l
migration is a dynamic process that is regulated by the for-
mation or turnover of focal contacts. Focal adhesion
kinase (FAK) is the key member of the focal contact
assembly and FAK activation is required for optimal cell
motility [39]. TM treatment significantly inhibited FAK
activation as well as the activation of LOX. LOX, a cop-
per-dependent amine oxidase, was initially reported as
responsible for the catalysis of collagen and elastin cross-
linking within the extracellular matrix [40]. However,
recent work has shown that LOX regulates a number of
cellular functions including cell migration via the activa-
tion of FAK/Src pathway [41,24]. Therefore, TM may be
inhibiting tumor cell migration by inhibiting FAK activa-
tion via lysyl oxidase. We further examined the role of TM
in tumor cell invasiveness by using Matrigel invasion
assay. TM treatment significantly inhibited oral squamous
cell invasion through Matrigel. Matrix metalloproteinases
(MMPs) play an important role in tumor cell invasiveness
by digesting the extracellular matrix. In HNSCC, MMP-2
Figure 4 TM treatment significantly inhibits oral squamous cell motility. A-B; OSCC-3 cells were cultured on top of a field of microscopic
fluorescent beads in the following culture conditions: in the absence of serum and TM (S-TM-); in the presence of serum but no TM (S+TM-); in
the absence of serum but presence of TM (S-TM+) or in the presence of serum and TM (S+TM+). After a 16-hours incubation period, cells were
fixed and areas of clearing in the fluorescent bead field corresponding to phagokinetic cell tracks were quantified using NIH ScionImager. C; LOX
catalytic activity was measured in whole-cell lysates of untreated (NT) or TM treated OSCC-3 cells (30 minutes). *, represents a significant
difference (p < 0.05) as compared to the control group. D; Whole cell lysates of untreated or TM treated OSCC-3 cells were separated using 4-
12% NuPAGE Bis-Tris gels and probed with anti-phospho-FAK antibody. Equal sample loading was verified by stripping the blots and re-probing
with anti-tubulin antibody.
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Page 8 of 11and MMP-9 have been shown to be involved in tumor cell
invasion [42,43]. Our results demonstrate that tumor cells
co-cultured with EC-Bcl-2 showed marked increase in
activated MMP-2 as compared to tumor cells co-cultured
with EC-VC. TM treatment of OSCC-3 and EC-Bcl-2 sig-
nificantly inhibited MMP-2 production. This TM-
mediated decrease in MMP-2 production could be due to
its inhibitory effect on FAK as it has been shown that
blocking of FAK activity by either dominant negative
mutants or antisence treatment significantly decreases
MMP expression [44,45].
Once the tumor cells invade through the matrix to
enter the circulation, they have to survive the harsh cir-
culatory conditions to successfully metastasize to distal
sites. We next examined if TM treated affect tumor cell
survival in circulation by using tail vein metastasis
model. TM treatment significantly inhibited tumor
metastasis to lungs in the SCID mouse model. To
further examine if TM treatment promotes tumor cell
death (anoiks) in non-adhering conditions, we cultured
Figure 5 TM treatment significantly inhibits oral squamous cell
invasiveness. TM effect on tumor cell invasiveness was examined
by Matrigel invasion assay. A; representative photomicrographs of
invaded cells with (TM+) or without TM (TM-) treatment.B; number
of tumor cells that had invaded through the Matrigel were counted
in 5 high power fields. *, represents a significant difference (p <
0.05) as compared to the control group. C; Culture supernatants
from OSCC-3 cells co-cultured with EC-Bcl-2 or EC-VC were resolved
using 10% polyacrylamide gelatin gels. After electrophoresis, the
gels were developed and stained by 0.5% Coomassie Brilliant Blue
R-250 solution to visualize the bands. D; the band density was
measured and expressed as average band density. *, represents a
significant difference (p < 0.05) as compared to the OSCC-3-EC-VC
group and **, represents a significant difference (p < 0.05) as
compared to the OSCC-3-EC-Bcl-2 group.
Figure 6 TM treatment significantly enhanced oral squamous
cell anokis. A; OSCC-3 cells were cultured either in normal
adherent conditions (Ad) or non-adherent conditions (Non-Ad) for
different time intervals. At the end of incubation, cells were carefully
retrieved and analyzed by TUNEL staining for anoikis using flow
cytometry. * represents a significant difference (p < 0.05) as
compared to the control group. B; OSCC-3 cells were cultured in
non-adherent conditions for different time intervals. Whole cell
lysates of untreated or TM treated OSCC-3 cells were separated
using 4-12% NuPAGE Bis-Tris gels and probed with anti-phospho-
p38MAPK, and XIAP antibody. Equal sample loading was verified by
stripping the blots and re-probing with anti-tubulin antibody.
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absence of TM. TM treatment significantly enhanced
tumor cell anoikis. Interestingly, TM treatment did not
affect OSCC-3 survival in adherent condition. TM could
be promoting tumor cell anoikis by increasing oxidative
stress (p38 MAPK activation) in the cells by down mod-
ulating superoxide dismutase (SOD) and X-linked inhi-
bitor of apoptosis (XIAP) , as copper is a cofactor for
both SOD and XIAP proteins [30,46]. SOD protects
cells from oxidative stress by catalyzing the dispropor-
tionation of superoxide to hydrogen peroxide [47],
whereas XIAP protein modulates oxidative stress by
binding to apoptosis-inducing factor (AIF) [46]. In addi-
tion, XIAP has been shown to promote cell survival by
directly binding to caspase 3 and inhibiting its function
by blocking substrate binding [48].
Conclusions
In conclusion, our results demonstrate that TM signifi-
cantly inhibits head and neck tumor metastasis by mod-
ulating a number of critical steps involved in tumor
metastasis cascade including angiogenesis, tumor cell
motility, invasiveness and tumor cell anoikis. Therefore,
TM with its low toxicity profile and good oral bioavail-
ability is a potentially novel candidate to control tumor
metastasis in head and neck cancer patients.
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